Why the study?
Does flecainide safely and effectively restore and maintain sinus rhythm in patients with atrial fibrillation without significant structural heart disease?
Does flecainide safely and effectively restore and maintain sinus rhythm in patients with atrial fibrillation without significant structural heart disease?
Flecainide is a safe and effective first-line treatment for restoring and maintaining sinus rhythm in patients with atrial fibrillation who lack significant structural heart disease.
Answers are grounded in this paper and cite their sources.
May support flecainide as first-line in eligible AF patients; leaves open prospective confirmation in contemporary cohorts.
Atrial fibrillation (AF) is the most common arrhythmia in clinical practise and its prevalence is increasing. Over the last 25 years, flecainide has been used extensively worldwide, and its capacity to reduce AF symptoms and provide long-term restoration of sinus rhythm (SR) has been well documented. The increased mortality seen in patients treated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) study, published in 1991, still deters many clinicians from using flecainide, denying many new AF patients a valuable treatment option. There is now a body of evidence that clearly demonstrates that flecainide has a favourable safety profile in AF patients without significant left ventricular disease or coronary heart disease. As a result of this evidence, flecainide is now recommended as one of the first-line treatment options for restoring and maintaining SR in patients with AF under current treatment guidelines. The objective of this article is to review the literature pertaining to the pharmacological characteristics, safety and efficacy of flecainide, and to place this drug in the context of current therapeutic management strategies for AF.
No takes yet. Share an insight, caveat, or question.
Aliot et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: